Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Early patterns of adherence in adolescents initiating highly active antiretroviral therapy predict long-term adherence, virologic, and immunologic control.

Lindsey JC, Bosch RJ, Rudy BJ, Flynn PM.

AIDS Patient Care STDS. 2009 Oct;23(10):799-801. doi: 10.1089/apc.2009.0081. No abstract available.

2.

Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy.

Flynn PM, Rudy BJ, Douglas SD, Lathey J, Spector SA, Martinez J, Silio M, Belzer M, Friedman L, D'Angelo L, McNamara J, Hodge J, Hughes MD, Lindsey JC; Pediatric AIDS Clinical Trial Group 381 Study Team..

J Infect Dis. 2004 Jul 15;190(2):271-9. Epub 2004 Jun 18.

PMID:
15216461
3.

Long-term observation of adolescents initiating HAART therapy: three-year follow-up.

Flynn PM, Rudy BJ, Lindsey JC, Douglas SD, Lathey J, Spector SA, Martinez J, Silio M, Belzer M, Friedman L, D'Angelo L, Smith E, Hodge J, Hughes MD; PACTG 381 Study Team..

AIDS Res Hum Retroviruses. 2007 Oct;23(10):1208-14.

PMID:
17961106
4.

Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence.

Press N, Tyndall MW, Wood E, Hogg RS, Montaner JS.

J Acquir Immune Defic Syndr. 2002 Dec 15;31 Suppl 3:S112-7. Review.

PMID:
12562032
5.

A meta-analysis of adherence to antiretroviral therapy and virologic responses in HIV-infected children, adolescents, and young adults.

Kahana SY, Rohan J, Allison S, Frazier TW, Drotar D.

AIDS Behav. 2013 Jan;17(1):41-60. doi: 10.1007/s10461-012-0159-4. Review.

PMID:
22411426
6.

Medication possession ratio associated with short-term virologic response in individuals initiating antiretroviral therapy in Namibia.

Hong SY, Jerger L, Jonas A, Badi A, Cohen S, Nachega JB, Parienti JJ, Tang AM, Wanke C, Terrin N, Pereko D, Blom A, Trotter AB, Jordan MR.

PLoS One. 2013;8(2):e56307. doi: 10.1371/journal.pone.0056307. Epub 2013 Feb 28.

7.

Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus.

Murphy DA, Belzer M, Durako SJ, Sarr M, Wilson CM, Muenz LR; Adolescent Medicine HIV/AIDS Research Network..

Arch Pediatr Adolesc Med. 2005 Aug;159(8):764-70.

PMID:
16061785
8.

Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.

Lima VD, Harrigan R, Murray M, Moore DM, Wood E, Hogg RS, Montaner JS.

AIDS. 2008 Nov 12;22(17):2371-80. doi: 10.1097/QAD.0b013e328315cdd3.

PMID:
18981777
9.
10.

Patient, caregiver and regimen characteristics associated with adherence to highly active antiretroviral therapy among HIV-infected children and adolescents.

Martin S, Elliott-DeSorbo DK, Wolters PL, Toledo-Tamula MA, Roby G, Zeichner S, Wood LV.

Pediatr Infect Dis J. 2007 Jan;26(1):61-7.

PMID:
17195708
11.

Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: week 60 results from the PACTG 381 cohort.

Rudy BJ, Lindsey JC, Flynn PM, Bosch RJ, Wilson CM, Hughes ME, Douglas SD; Pediatric Aids Clinical Trials Group 381 Study Team..

AIDS Res Hum Retroviruses. 2006 Mar;22(3):213-21.

PMID:
16545007
12.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV..

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
13.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for the Treatment of HIV..

MMWR Recomm Rep. 2002 May 17;51(RR-7):1-55.

14.

A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapy.

Collier AC, Ribaudo H, Mukherjee AL, Feinberg J, Fischl MA, Chesney M; Adult AIDS Clinical Trials Group 746 Substudy Team..

J Infect Dis. 2005 Oct 15;192(8):1398-406. Epub 2005 Sep 14.

PMID:
16170757
15.

Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy.

Tuldrà A, Fumaz CR, Ferrer MJ, Bayés R, Arnó A, Balagué M, Bonjoch A, Jou A, Negredo E, Paredes R, Ruiz L, Romeu J, Sirera G, Tural C, Burger D, Clotet B.

J Acquir Immune Defic Syndr. 2000 Nov 1;25(3):221-8.

PMID:
11115952
16.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
17.

Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels.

Parienti JJ, Das-Douglas M, Massari V, Guzman D, Deeks SG, Verdon R, Bangsberg DR.

PLoS One. 2008 Jul 30;3(7):e2783. doi: 10.1371/journal.pone.0002783.

18.

Adherence issues in children and adolescents receiving highly active antiretroviral therapy.

Goode M, McMaugh A, Crisp J, Wales S, Ziegler JB.

AIDS Care. 2003 Jun;15(3):403-8.

PMID:
12745395
19.

Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.

Scherpbier HJ, Bekker V, Pajkrt D, Jurriaans S, Lange JM, Kuijpers TW.

Pediatrics. 2007 Mar;119(3):e705-15. Epub 2007 Feb 16.

PMID:
17308244
20.

The eldest of older adults living with HIV: response and adherence to highly active antiretroviral therapy.

Brañas F, Berenguer J, Sánchez-Conde M, López-Bernaldo de Quirós JC, Miralles P, Cosín J, Serra JA.

Am J Med. 2008 Sep;121(9):820-4. doi: 10.1016/j.amjmed.2008.05.027.

PMID:
18724973

Supplemental Content

Support Center